7ZQW
Structure of the SARS-CoV-1 main protease in complex with AG7404
Summary for 7ZQW
Entry DOI | 10.2210/pdb7zqw/pdb |
Related | 7P35 7ZQV |
Descriptor | 3C-like proteinase nsp5, ethyl (4R)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate (3 entities in total) |
Functional Keywords | protease, inhibitor, sars-cov-1, viral protein |
Biological source | Severe acute respiratory syndrome coronavirus |
Total number of polymer chains | 1 |
Total formula weight | 34402.19 |
Authors | Muriel-Goni, S.,Fabrega-Ferrer, M.,Herrera-Morande, A.,Coll, M. (deposition date: 2022-05-03, release date: 2022-12-28, Last modification date: 2024-01-31) |
Primary citation | Fabrega-Ferrer, M.,Herrera-Morande, A.,Muriel-Goni, S.,Perez-Saavedra, J.,Bueno, P.,Castro, V.,Garaigorta, U.,Gastaminza, P.,Coll, M. Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404. Antiviral Res., 208:105458-105458, 2022 Cited by PubMed Abstract: Severe acute respiratory syndrome coronaviruses 1 and 2 (SARS-CoV-1 and SARS-CoV-2) pose a threat to global public health. The 3C-like main protease (M), which presents structural similarity with the active site domain of enterovirus 3C protease, is one of the best-characterized drug targets of these viruses. Here we studied the antiviral activity of the orally bioavailable enterovirus protease inhibitor AG7404 against SARS-CoV-1 and SARS-CoV-2 from a structural, biochemical, and cellular perspective, comparing it with the related molecule rupintrivir (AG7800). Crystallographic structures of AG7404 in complex with SARS-CoV-1 M and SARS-CoV-2 M and of rupintrivir in complex with SARS-CoV-2 M were solved, revealing that all protein residues interacting with the inhibitors are conserved between the two proteins. A detailed analysis of protein-inhibitor interactions indicates that AG7404 has a better fit to the active site of the target protease than rupintrivir. This observation was further confirmed by biochemical FRET assays showing IC values of 47 μM and 101 μM for AG7404 and rupintrivir, respectively, in the case of SARS-CoV-2 M. Equivalent IC values for SARS-CoV-1 also revealed greater inhibitory capacity of AG7404, with a value of 29 μM vs. 66 μM for rupintrivir. Finally, the antiviral activity of the two inhibitors against SARS-CoV-2 was confirmed in a human cell culture model of SARS-CoV-2 infection, although rupintrivir showed a higher potency and selectivity index in this assay. PubMed: 36336176DOI: 10.1016/j.antiviral.2022.105458 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.53 Å) |
Structure validation
Download full validation report